The purpose of this study is to assess the safety and efficacy of switching from Remicade to
the biosimilar treatment Remsima in patients with rheumatoid arthritis, spondyloarthritis,
psoriatic arthritis, ulcerative colitis, Crohn's disease and chronic plaque psoriasis